Geoff Nichol Appointed to Millendo Therapeutics Board of Directors

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced that Geoff Nichol, M.B., Ch.B., M.B.A., has been appointed to the Board of Directors. Dr. Nichol currently serves as Chief Medical Officer at BioMarin where he oversees an active portfolio of clinical development programs and has led multiple programs through late-stage clinical studies and regulatory approval.